We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Mind the gap

19 December 2006 By Robert Cyran

A consortium of private equity firms may have beaten it in the $11bn buyout of the orthopaedics maker, sending S&N shares higher. But you can bet Biomet will be back on the menu in a few years time, after its options probe is finished and at a higher price than now.

This content is for Subscribers only

 

Mind the gap

19 December 2006 By Robert Cyran

A consortium of private equity firms may have beaten it in the $11bn buyout of the orthopaedics maker, sending S&N shares higher. But you can bet Biomet will be back on the menu in a few years time, after its options probe is finished and at a higher price than now.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)